Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Pd-1/Pd-L1 Blockade Therapy With Atezolizumab: A New Paradigm in the Treatment of Non-Small Cell Lung Cancer (Nsclc) Publisher



Moradi S1 ; Sarikhani P2 ; Albadr RJ3 ; Taher WM4 ; Alwan M5 ; Jawad MJ6 ; Mushtaq H7 ; Vakilzadehian N8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Departments of Internal Medical, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Medicine Department, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Ahl Al Bayt University, Kerbala, Iraq
  4. 4. College of Nursing, National University of Science and Technology, Dhi Qar, Iraq
  5. 5. Pharmacy College, Al-Farahidi University, Baghdad, Iraq
  6. 6. Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq
  7. 7. Gilgamesh Ahliya University, Baghdad, Iraq
  8. 8. Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Tehran, Tehran, Iran

Source: Discover Oncology Published:2025


Abstract

Now, platinum-based chemotherapy is used as the first-line treatment for advanced non-small cell lung cancer (NSCLC). Interestingly, a combination of immune checkpoint inhibitors, such as mepolizumab, with other targeted therapies and chemotherapy help to make a significant improvement. Atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1), blocks PD-1 activation and results in T-cell activity against tumor cells. As the second-line treatment of advanced or metastatic NSCLC, atezolizumab plus chemotherapy was approved in 2017 concerning the clinical benefit of the phase III OAK trials. Atezolizumab, compared with docetaxel, remarkably increased overall survival (OS) and showed promising efficacy and tolerability in the treatment of advanced NSCLC.Research on atezolizumab's application in neoadjuvant (pre-surgery) and adjuvant (post-surgery) contexts is ongoing. It is now undergoing trials to assess its efficacy in these settings, which may broaden its place in the NSCLC therapy spectrum and enhance long-term results. This paper briefly summarizes the clinical data of atezolizumab therapy alone or in combination with other therapeutics for NSCLC therapy. © The Author(s) 2025.